Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in ...

DUBLIN , April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS ) announced today that management will participate in a webcast panel discussion " Development of Orexin Receptor Agonist in Sleep-Wake Disorders " at the upcoming 24 th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT ( 4:45 p.m. BST ). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia . Headquartered in Ireland , Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio . For more information, please visit Alkermes ' website at www.alkermes.com .